Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Ryan H. Saadi M.D., M.P.H, M.P.H. | Co-Founder, CEO & Chairman | 501k | -- | 1965 |
| Mr. Kirti Desai CPA | Chief Financial Officer | 300k | -- | 1957 |
| Dr. Neal Flomenberg M.D. | Chief Scientific Officer and Global R&D Lead | 350k | -- | 1954 |
| Mr. Stephen Chen M.B.A. | Chief Technical Officer | -- | -- | -- |
| Mr. Mittul Mehta | Chief Information Officer & Head of Tevogen.ai | -- | -- | -- |
| Mr. Tapan V. Shah | Head of Investor Relations & Corporate Development | -- | -- | -- |
| Mr. Sadiq Khan M.B.A. | Chief Commercial Officer | -- | -- | 1962 |
Tevogen Bio Holdings Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available